Century Therapeutics, Inc. (IPSC) analyst actions
Rating and price-target actions on IPSC in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IPSC overview →
1 measured IPSC analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders | Press release | -1.63% | -3.02% |
Keep exploring
More IPSC: earnings → · SEC filings → · IPSC overview →